Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated by Analysts at HC Wainwright

Stock analysts at HC Wainwright began coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report released on Friday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $42.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 114.94% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating on the stock. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target for the company. Finally, Morgan Stanley initiated coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Bicara Therapeutics presently has an average rating of “Buy” and an average target price of $43.00.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $19.54 on Friday. Bicara Therapeutics has a 52 week low of $17.41 and a 52 week high of $28.09. The business has a 50 day moving average of $21.82.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, equities research analysts predict that Bicara Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In related news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the transaction, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder James E. Flynn purchased 70,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now directly owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This represents a 8.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BCAX. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics in the third quarter worth $229,000. Barclays PLC bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $255,000. Jane Street Group LLC purchased a new stake in shares of Bicara Therapeutics during the third quarter valued at approximately $309,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of Bicara Therapeutics in the third quarter worth approximately $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Bicara Therapeutics in the third quarter worth about $462,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.